臨床泌尿器科66巻1号

2012年01月発行

特集 進行性腎癌に対する分子標的治療薬・薬剤選択ガイド

分子標的治療における治療効果を予測するバイオマーカーの展望

著者： 水野隆一¹ 大家基嗣¹

所属機関： ¹慶應義塾大学医学部泌尿器科学教室

ページ範囲：P.51 - P.55

要旨　進行性腎細胞癌に対する薬物治療は，新規分子標的薬の登場に伴って，従来のサイトカイン療法から分子標的治療へと移行してきている。さらなる新薬の開発によって，治療薬の選択肢は増加してきているものの，有効な治療効果を予測するようなバイオマーカーはいまだ明らかにされていない。現在は腎細胞癌のバイオマーカー候補の探索段階にあり，蛋白質にとどまらずSNPsなどの遺伝子関連マーカーなども注目されている。症例の蓄積によって今後バイオマーカーの分野は発展してくることが予想される。分子標的治療薬の効果を薬剤投与開始前に予測するバイオマーカーの同定により，より有効な分子標的治療の提供が期待される。

参考文献

1）Toyooka S, Kiura K and Mitsudomi T：EGFR mutation and response of lung cancer to gefitinib. N Engl J Med 352：2136, 2005

2）Van Cutsem E, Köhne CH, Hitre E, et al：Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360：1408-1417, 2009

3）Maxwell PH, Wiesener MS, Chang GW, et al：The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399：271-275, 1999

4）Motzer RJ, Mazumdar M, Bacik J, et al：Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17：2530-2540, 1999

5）Motzer RJ, Bacik J, Murphy BA, et al：Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20：289-296, 2002

6）Heng DY, Xie W, Regan MM, et al：Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents：results from a large, multicenter study. J Clin Oncol 27：5794-5799, 2009

7）Patil S, Figlin RA, Hutson TE, et al：Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 22：295-300, 2011

8）Bono P, Rautiola J, Utriainen T, et al：Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma. Acta Oncol 50：569-573, 2011

9）Beuselinck B, Oudard S, Rixe O, et al：Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol 22：794-800, 2011

10）Baldazzi V, Tassi R, Lapini A, et al：The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients：a prospective single-center study. Urol Oncol, 2010 Sep 28.［Epub ahead of print］

11）Choi H, Charnsangavej C, Faria SC, et al：Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate：proposal of new computed tomography response criteria. J Clin Oncol 25：1753-1759, 2007

12）Nathan PD, Vinayan A, Stott D, et al：CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. Cancer Biol Ther 9：15-19, 2010

13）Gossage L and Eisen T：Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat Rev Clin Oncol 7：277-288, 2010

14）Porta C, Paglino C, De Amici M, et al：Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. Kidney Int 77：809-815, 2010

15）Escudier B, Eisen T, Stadler WM, et al：Sorafenib for treatment of renal cell carcinoma：final efficacy and safety results of the phase Ⅲ treatment approaches in renal cancer global evaluation trial. J Clin Oncol 10：3312-3318, 2009

16）Horiguchi A, Oya M, Uchida A, et al：Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma. J Urol 169：710-713, 2003

17）Hara S, Oya M, Mizuno R, et al：Akt activation in renal cell carcinoma：contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann Oncol 16：928-933, 2005

18）Jonasch E, Corn P, Pagliaro LC, et al：Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma：clinical and biomarker analysis. Cancer 116：57-65, 2010

19）Lin J, Horikawa Y, Tamboli P, et al：Genetic variations in microRNA-related genes are associated with survival and recurrence in patients with renal cell carcinoma. Carcinogenesis 31：1805-1812, 2010

20）Kim JJ, Vaziri SA, Elson P, et al：Role of VEGF and VEGFR2 single nucleotide polymorphisms（SNPs）in predicting treatment-induced hypertension（HTN）and clinical outcome（CO）in metastatic clear cell RCC（mccRCC）patients（pts）treated with sunitinib. J Clin Oncol 28：15s, 2010（suppl；abstr 4629）

21）Xu CF, Bing NX, Ball HA, et al：Pazopanib efficacy in renal cell carcinoma：evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin Oncol 29：2557-2564, 2011